1. Academic Validation
  2. Discovery of Novel Small Molecule Dual Inhibitor Targeting Toll-Like Receptors 7 and 9

Discovery of Novel Small Molecule Dual Inhibitor Targeting Toll-Like Receptors 7 and 9

  • J Chem Inf Model. 2024 Jul 8;64(13):5090-5107. doi: 10.1021/acs.jcim.4c00578.
Muhammad Haseeb 1 2 Yang Seon Choi 2 Mahesh Chandra Patra 2 Uisuk Jeong 1 2 Wang Hee Lee 2 Naila Qayyum 2 Hongjoon Choi 1 2 Wook Kim 2 Sangdun Choi 1 2
Affiliations

Affiliations

  • 1 S&K Therapeutics, Ajou University, Campus Plaza 418, 199 Worldcup-ro, Yeongtong-gu, Suwon 16502, Korea.
  • 2 Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea.
Abstract

The aberrant secretion of proinflammatory cytokines by immune cells is the principal cause of inflammatory diseases, such as systemic lupus erythematosus and rheumatoid arthritis. Toll-like Receptor 7 (TLR7) and TLR9, sequestered to the endosomal compartment of dendritic cells and macrophages, are closely associated with the initiation and progression of these diseases. Therefore, the development of drugs targeting dysregulated endosomal TLRs is imperative to mitigate systemic inflammation. Here, we applied the principles of computer-aided drug discovery to identify a novel low-molecular-weight compound, TLR inhibitory compound 10 (TIC10), and its potent derivative (TIC10g), which demonstrated dual inhibition of TLR7 and TLR9 signaling pathways. Compared to TIC10, TIC10g exhibited a more pronounced inhibition of the TLR7- and TLR9-mediated secretion of the proinflammatory cytokine tumor necrosis factor-α in a mouse macrophage cell line and mouse bone marrow dendritic cells in a concentration-dependent manner. While TIC10g slightly prevented TLR3 and TLR8 activation, it had no impact on cell surface TLRs (TLR1/2, TLR2/6, TLR4, or TLR5), indicating its selectivity for TLR7 and TLR9. Additionally, mechanistic studies suggested that TIC10g interfered with TLR9 activation by CpG DNA and suppressed downstream pathways by directly binding to TLR9. Western blot analysis revealed that TIC10g downregulated the phosphorylation of the p65 subunit of nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinases (MAPKs), including extracellular-signal-regulated kinase, p38-MAPK, and c-Jun N-terminal kinase. These findings indicate that the novel ligand, TIC10g, is a specific dual inhibitor of endosomal TLRs (TLR7 and TLR9), disrupting MAPK- and NF-κB-mediated proinflammatory gene expression.

Figures
Products